

YOU ARE INVITED

to an amazing night in the city with...

KARMANOS CANCER FOUNDATION

Climbing to the Future with Cancer Research

Thursday, October 20, 2022

5:30 – 9:30 p.m.

CHROMA

2937 E. Grand Blvd., Detroit, MI 48201

Complimentary parking in a gated lot off of Beaubien

The amazing evening includes...

- *Strolling cuisine and libations*
- *Live music by Intrigue*
- *Live raffle*
- *Casual business attire*



CANCER INSTITUTE

Wayne State University

KARMANOS CANCER FOUNDATION

Karmanos Cancer Foundation Board of Directors

Dawn Aronoff	Peter Karmanos, Jr.
Greg Avsharian	Kelley LaFontaine
Jim Bennethum	Mary Matuja
Michael Duhaime	Debra Partrich
Mark Flynn	Dick Purtan
Adnan Hammad	Eunice Ring
Ellen Hill Zeringue	Deborah Savoie
Joseph Uberti, M.D., Ph.D.	



CANCER INSTITUTE

Wayne State University

KARMANOS CANCER FOUNDATION

KARMANOS CANCER INSTITUTE CONTINUES TO CLIMB TO THE FUTURE WITH CANCER RESEARCH:

- 1964: Dr. Jerome Horowitz synthesized AZT – saved millions of lives as the first effective AIDS treatment.
- 1973: Dr. Herbert Soule developed MCF-7, the first sustainable cell line which became the standard for human breast cancer research and later the drug tamoxifen was created from this cell line.
- 1974: Drs. Vainutis Vaitkevicius, Norman Nigro, Basil Considine, reported chemo radiation as the treatment of choice for anal cancer.
- **1978: Karmanos Cancer Institute was the first National Cancer Institute (NCI) - Designated Comprehensive Cancer Center in Michigan. We set the standard for oncology care and research for the state.**
- 1998: Dr. Anthony Shields developed FLT as a new positron emission tomography tracer to identify cancer cells.
- 1999: Dr. Wei-Zen Wei developed HER2 DNA breast cancer vaccine.
- 2004: Clinical prototype of an ultrasound tomography (UST) device was created at Karmanos.
- 2017: CAR-T cell therapy received FDA approval – Karmanos is 1 of 18 sites in the world that participated in its development.
- 2020 Today we are **one of 53** Comprehensive Cancer Centers in the United States.

RECOGNIZED FOR RESEARCH

- The Barbara Ann Karmanos Cancer Institute received its **renewal of its National Cancer Institute Core Grant. This renewal extends Karmanos' prestigious NCI designation through 2025. Karmanos has maintained its NCI Comprehensive Cancer Center designation for more than 45 years!**
- Comprehensive Cancer Centers have the ability to translate scientific findings from the laboratory to the patient's bedside with the ability to tailor and personalize the treatment. In many cases, innovative treatments, particularly clinical trials, are only available through NCI-Designated Comprehensive Cancer Centers and their affiliates. Comprehensive Cancer Centers undergo a rigorous review every five years to maintain their designation.
- Offers patients with more than **800 cancer-specific scientific investigations and 300 active clinical trials.**
- **Karmanos is a leader in the nation** for enrolling minority patients in clinical trials and has the most diverse patient population among cancer centers nationwide.
- The Karmanos Network in urban, suburban and rural locations provides complex, ethnically diverse population-based data to support the early detection, treatment and eventual eradication of cancer.
- **Karmanos has 16 treatment centers throughout Michigan** - from Detroit to Petoskey and Lansing to Bad Axe and Northwest Ohio.